Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.1K
1.1K
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

50
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
50
EPS and iPS Cells in Disease Research01:21

EPS and iPS Cells in Disease Research

3.2K
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
3.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prophylaxis and management of thromboembolism in pnh patients: an italian survey.

Annals of hematology·2026
Same author

Allogeneic stem cell transplantation in adult Ph-like acute lymphoblastic leukemia. Results from two consecutive GIMEMA protocols.

Bone marrow transplantation·2026
Same author

Early software-assisted response predicts survival in a prospective cohort of 258 newly diagnosed cGvHD patients.

Bone marrow transplantation·2026
Same author

Dynamics of IDH1/2 mutated clones in acute myeloid leukemia challenge their use as universal MRD markers.

Blood cancer journal·2026
Same author

Pre-emptive versus empirical antifungal therapy in patients with febrile neutropenia with acute leukaemia: a GIMEMA study.

JAC-antimicrobial resistance·2026
Same author

Targeted Therapies Combined with Intensive Chemotherapy in Fit Acute Myeloid Leukemia: Past Developments, Current Evidence, and Future Therapeutic Paradigms.

Journal of clinical medicine·2026

Related Experiment Video

Updated: Apr 22, 2026

MISSION LentiPlex Pooled shRNA Library Screening in Mammalian Cells
09:12

MISSION LentiPlex Pooled shRNA Library Screening in Mammalian Cells

Published on: December 21, 2011

21.6K

Plerixafor: what we still have to learn.

Francesco Lanza1, Angelo Gardellini, Daniele Laszlo

  • 1Hematology Institute, Hospital of Cremona , Cremona , Italy.

Expert Opinion on Biological Therapy
|October 16, 2014
PubMed
Summary

Plerixafor, a stem cell mobilizer, is safe and effective with G-CSF for patients with non-Hodgkin

Area of Science:

  • Hematology
  • Pharmacology
  • Oncology

Background:

  • Plerixafor is indicated with G-CSF for hematopoietic stem cell mobilization in non-Hodgkin's lymphoma and multiple myeloma.
  • It is used for autologous transplantation when patients have low CD34(+) cell counts or poor initial collection yields.

Discussion:

  • The combination of plerixafor, chemotherapy, and G-CSF demonstrates safety and efficacy in most patients.
  • Debated questions regarding plerixafor's optimal use and potential applications remain.

Key Insights:

  • Plerixafor effectively mobilizes hematopoietic stem cells, improving collection success in challenging cases.
  • The drug's safety profile is favorable when used with standard mobilization protocols.

Outlook:

Keywords:
autologous transplantationmobilizationperipheral blood stem cellsplerixafor

More Related Videos

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
09:02

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

11.4K
The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
12:22

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

33.1K

Related Experiment Videos

Last Updated: Apr 22, 2026

MISSION LentiPlex Pooled shRNA Library Screening in Mammalian Cells
09:12

MISSION LentiPlex Pooled shRNA Library Screening in Mammalian Cells

Published on: December 21, 2011

21.6K
Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
09:02

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

11.4K
The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
12:22

The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers

Published on: January 22, 2013

33.1K
  • Further research is needed to explore novel applications and optimize plerixafor treatment strategies.
  • Identifying new patient populations and refining existing protocols will enhance plerixafor's therapeutic value.